Retatrutide test results: how often vials pass lab testing
Retatrutide is the most tested compound in a public peptide testing database. Here is how often those vials pass, what a fail means, and why there is still no approved version to compare against.
Of the last 193 Retatrutide samples with a result in Finnrick's public lab-testing database, 135 passed and 58 failed: 70 percent of Retatrutide test results were a pass. Another 7 came back incomplete and are left out. Finnrick has published 4,828 Retatrutide tests from 417 sellers since 17 Dec 2024.
Retatrutide is an investigational once-weekly peptide that acts on three receptors at once: GLP-1, GIP and glucagon. Phase 3 trials are underway. There is no approved retatrutide product, so every vial sold online today is a research-labelled product, and a lab test is the only check a buyer has on what is inside.
The short version
- 70 percent of recent samples passed. 135 passed and 58 failed, of the last 193 with a result.
- It is not FDA-approved. There is no approved product, no prescribing information and no pharmacy route outside a clinical trial.
- A pass is a narrow result. It covers identity, purity and fill for the vial that was tested. It does not cover endotoxin, sterility or the next batch.
- We do not name sellers. The numbers describe the market, not any one shop.
Retatrutide test results in numbers
| Measure | Retatrutide |
|---|---|
| Published tests | 4,828 |
| Sellers with at least one test | 417 |
| First and latest test | 17 Dec 2024 to 10 Nov 2026 |
| Recent results counted | 193 (7 incomplete left out) |
| Passed | 135 |
| Failed | 58 |
| Pass rate | 70% |
| Rank by pass rate | 3 of 14 on our peptide test results page |
Figures from Finnrick's public Retatrutide page, checked on 12 November 2026. They will change as new results come in.
What counts as a pass or a fail
These figures use Finnrick's "Purity focus" standard, the one its public pages show. A sample passes when its purity is at least 99.5 percent and the amount in the vial is within 35 percent of the label. A sample that turns out to be a different molecule fails under every standard Finnrick uses. Endotoxin testing is not required under this standard, so a pass says nothing about endotoxin or sterility.
The pass rate counts passes and fails among the most recent results on Finnrick's public page, up to 200, and leaves out tests that came back incomplete. Finnrick says it sources samples from sellers and sends them to third-party labs, with HPLC as the main method. Its methodology page has the detail.
Is retatrutide FDA-approved?
No. Retatrutide is investigational, and our retatrutide page and retatrutide trials page track the phase 3 programme. It is not one of the six peptides named in HHS's October 2026 draft enforcement discretion policy for compounding pharmacies, so no pharmacy can make it for you on a prescription either. A "research use only" label does not change any of that. It means the product is not an approved drug and was not made under drug manufacturing rules.
Why retatrutide is the most tested peptide
Finnrick has published 4,828 retatrutide tests from 417 sellers since 17 Dec 2024, more than for any other compound it lists. The reason is simple. With semaglutide or tirzepatide, a buyer can at least compare a research vial with an approved pen. With retatrutide there is nothing to compare against, so people test.
Volume does not make the product cleaner. Of the recent results, 58 failed. That is close to one in three. A large number of tests tells you the market is busy and the failures are documented, not that any one seller has fixed them.
Before you buy Retatrutide
No prescriber can write for an approved retatrutide product, because none exists. Taking part in a clinical trial is the only supervised way to get it today. Anything else is a research-labelled vial, and the checks below are the minimum before you trust one.
Before any order, three checks come first: the steps in how to vet a peptide supplier, an independent result for your own lot (how to get peptides tested), and the legal picture in is it legal to buy peptides. Products sold as research use only are not FDA-approved drugs, and a passing test does not make one safe to use.
Peptide AI is building a marketplace with two ways to buy: on a prescription through licensed telehealth, for what can legally be prescribed, or from vetted suppliers with an independent lab report you read before you order. It is not open yet. Early access is here.
Questions people ask
What percentage of Retatrutide fails lab testing?
In Finnrick's public test database, 58 of the last 193 Retatrutide samples with a result failed, which is 30 percent, and 135 passed. Tests that came back incomplete are left out.
Is Retatrutide FDA-approved?
It is not FDA-approved. There is no approved product, no prescribing information and no pharmacy route outside a clinical trial.
Does a passing lab test mean Retatrutide is safe?
No. A pass means the sample matched its label on identity, purity and fill under one standard. It does not cover endotoxin, sterility, other vials, or whether Retatrutide is safe or does anything in people.
Is retatrutide from research sellers real retatrutide?
Only a lab test can tell you. Under the standard used here, a sample that is not the labelled peptide fails outright, and 58 of the last 193 retatrutide samples failed on identity, purity or fill.
Sources
- Methodology, Finnrick, accessed 12 November 2026
- Retatrutide product page and public test history, Finnrick, accessed 12 November 2026
- HHS announces interim enforcement discretion for section 503A compounding with certain peptide bulk drug substances, Venable LLP, 6 November 2026
